Medicus Pharma Ltd. (MDCX) · Oct 7, 2026 · Other events

Medicus Pharma reverse split targets Nasdaq compliance

50:1 share consolidation — Effective October 12, 2026; every 50 shares become one

Medicus Pharma’s 50:1 share consolidation begins October 12 to address Nasdaq’s bid-price rule, but adds no new clinical progress.

Medicus Pharma is a clinical-stage biotech narrowing its portfolio around SkinJect for Gorlin syndrome and Teverelix-based precision-medicine programs, while also positioning CD228V as a precision-oncology asset. This filing is a listing repair, not a pipeline milestone. The company will consolidate its common shares 50-for-1 effective October 12, specifically to lift the bid price and regain compliance with Nasdaq’s minimum-bid requirement. 〔0〕

The economic effect is mechanical rather than fundamental. Every 50 existing shares become one new share, while voting rights and the underlying ownership percentage are unchanged; outstanding warrants, convertibles, and equity awards will be adjusted proportionately. 〔1〕 〔2〕 That can help the company clear a share-price listing hurdle, but it does not improve clinical data, cash generation, financing capacity, or the prospects of SkinJect and Teverelix.

The direction was already expected; the exact execution is the new information. Shareholders had authorized a consolidation of up to 50-for-1 at the June 3, 2026 annual meeting, so this announcement confirms the maximum ratio and sets the October 12 trading date rather than introducing a new strategic decision.

Bottom line: This removes an immediate Nasdaq bid-price obstacle, but it is a defensive capital-markets action rather than progress on Medicus Pharma’s drug-development story. It matters for maintaining the listing, not because the business itself advanced.

What to watch next

Post-consolidation trading begins October 12

Original filing on SEC EDGAR

More Medicus Pharma Ltd. news

Medicus Pharma reverse split targets Nasdaq compliance | MDCX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.